This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Agios (AGIO) Loss Wider Than Expected in Q4, Revenues Nil
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) posts wider-than-expected loss for the fourth quarter of 2021. It does not record any revenues in the quarter.
Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 5% and 5.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -1.34% and 3.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Arbutus Biopharma (ABUS) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.
Anixa (ANIX) COVID Compounds Prove Effective Against Omicron
by Zacks Equity Research
Anixa Biosciences' (ANIX) potential COVID-19 compounds show effectiveness against the Omicron variant of COVID-19.
Implied Volatility Surging for Arbutus Biopharma (ABUS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.
Arbutus Biopharma (ABUS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arbutus (ABUS) delivered earnings and revenue surprises of 0.00% and 41.53%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Arbutus Biopharma (ABUS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About Arbutus Biopharma (ABUS) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Arbutus Biopharma (ABUS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.
Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arbutus (ABUS) delivered earnings and revenue surprises of -9.52% and 12.35%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arbutus (ABUS) delivered earnings and revenue surprises of 4.55% and -45.40%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arbutus (ABUS) delivered earnings and revenue surprises of -9.52% and 12.49%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Arbutus Biopharma (ABUS) This Earnings Season?
by Zacks Equity Research
Arbutus Biopharma (ABUS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Implied Volatility Surging for Arbutus Biopharma (ABUS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.
Implied Volatility Surging for Arbutus Biopharma (ABUS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.
Implied Volatility Surging for Arbutus Biopharma (ABUS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arbutus (ABUS) delivered earnings and revenue surprises of -35.00% and -15.62%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Arbutus Biopharma (ABUS) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Arbutus Biopharma (ABUS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ABUS) Outperforming Other Medical Stocks This Year?
Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arbutus (ABUS) delivered earnings and revenue surprises of -8.70% and -17.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Arbutus Biopharma (ABUS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Arbutus Biopharma (ABUS) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: MRNA, DVAX Up on Coronavirus Treatment Updates, & More
by Zacks Equity Research
The biotech sector remains in focus with pipeline updates on coronavirus treatments.